GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » Cyclically Adjusted PB Ratio

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.77 (As of Jun. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Corvus Pharmaceuticals's current share price is $2.22. Corvus Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 was $2.90. Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.77.

The historical rank and industry rank for Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

CRVS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.79
Current: 0.75

During the past 10 years, Corvus Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.79. The lowest was 0.00. And the median was 0.00.

CRVS's Cyclically Adjusted PB Ratio is ranked better than
68.84% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs CRVS: 0.75

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Corvus Pharmaceuticals's adjusted book value per share data of for the fiscal year that ended in Dec23 was $0.789. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.90 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Corvus Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Corvus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.61

Corvus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.61 -

Competitive Comparison of Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Corvus Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.22/2.9
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corvus Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Corvus Pharmaceuticals's adjusted Book Value per Share data for the fiscal year that ended in Dec23 was:

Adj_Book=Book Value per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=0.789/129.4194*129.4194
=0.789

Current CPI (Dec23) = 129.4194.

Corvus Pharmaceuticals Annual Data

Book Value per Share CPI Adj_Book
201412 0.000 99.070 0.000
201512 -1.524 99.792 -1.976
201612 6.347 101.863 8.064
201712 4.032 104.011 5.017
201812 3.763 105.998 4.594
201912 2.544 108.420 3.037
202012 2.543 109.897 2.995
202112 2.087 117.630 2.296
202212 1.205 125.222 1.245
202312 0.789 129.419 0.789

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corvus Pharmaceuticals  (NAS:CRVS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Corvus Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corvus Pharmaceuticals (Corvus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
Executives
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
William Benton Jones officer: See Remarks 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Leiv Lea officer: Chief Financial Officer PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Miller Richard A Md director, officer: President and CEO PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell director 1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher officer: Chief Medical Officer 863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould director, 10 percent owner C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy officer: EVP Discovery Research CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt officer: SVP, Chief Business Officer 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner officer: V.P., Chemistry Research 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Headlines

From GuruFocus

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

By GuruFocusNews GuruFocusNews 07-09-2022